Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Overview on Dry Power Inhalers


Published on

An overview on Dry Powder Inhalers with market analysis. Showing the advantage of this popular delivery system

Published in: Health & Medicine
  • Be the first to comment

Overview on Dry Power Inhalers

  1. 1. Stuart Silverman – CEO & Founder
  2. 2. Major DPI Market Trends and Perspectives
  3. 3. Double digit growth on DPI market Western European Asthma/COPD market Oral, injectable,inhaled drugs CAGR 2008–2018: 4%* 2008 sales: $6.9 billion 2018 sales: $9.9 billion *Source: 2009–2018 forecast = Datamonitor; 2004–08 sales data from MIDAS, IMS Health Western Europe: France, Germany, UK, Spain, Italy Worldwide DPI Market Global Sales revenue $19 bn to $38 bn by 2015 ( GIA report 2010)
  4. 4. Key Drivers for Choice of Inhalation Technology Risk Risk •Innovation is long to be established •Safe, well-known inhalation solution •Technology mastering/in-house technology Patient’s need •Acceptability, convenience •Familiarity of patient group with device •Small / High volumes of drug Differentiation •Ability to get competitive advantage •Patent protection •Bring innovation, choice, diversity Performance •Technical performance (lung deposition, API protection) •Ability to effectively deliver the dose •Cost effectiveness
  5. 5. In the last six years Dry Powder Inhalers have continued to take share from the MDI market, a trend that we expect to continue for several reasons including patient preference and environmental impact. DPI- A growing technology *
  6. 6. 6 CapsulesBlister Reservoir Weaknesses •High dose variation •No ability to see remaining doses Strengths Accurate dosing Pre-metered dose Humidity protection •All-in-one system •COGs •Multidose (no handling) •No ability to see dose is effectively taken •More expensive than capsules •Control of inhaled dose •Flexibility: •number of doses, •remaining dose, emptied dose, •Potential for combination •API protection •Multidose inhaler •Easy to handle •All-in-one system •Handling •Device and capsule are separated Perceived Strengths and Weaknesses of DPIs Technologies
  7. 7. Trends in capsule-based DPI systems •Improving quantity of inhaled drug •100% protection of active ingredient •No humidity constraint • API improvement for less side-effects • Excipient-free •Ability to combine different APIs •Reduction of device size •Improving handling •Easier way of dispensing and removing the capsule •Pre-loaded system with several capsules •Ability to maintain cost low •Recycling material •Reusable / refill cartridge •Colored / Imprinted capsule •Same device for different capsule/application • Specific design to protect from copy Performance User-Friendly Eco-Friendly Differentiation
  8. 8. Two opposed trends in Inhalation Technology: ComplexSimple Product handling Less manipulation in between 2 doses Elderly patients, cognitive or physical impairment Fits naïve users Simple devices cheap to develop Fit developing market, large market size with strong economic pressure Being able to produce in very large number very quickly (pandemic) Patient convenience Device attributes / technology Extra attributes like counting dose, blocking system to avoid accidental charge of the next dose, cleanliness, monitoring dose intake for compliance Cost effectiveness Complex device offering innovation  Fits disease with few medications on the market to be able to deliver an innovative product both on API and delivery mechanism
  9. 9. Current and future applications Current Future MDIs is the historical device for inhalation Asthma COPD  Relatively sophisticated users: Want multi-dose solution, high number of dose, cost-effective solution  Naïve users: one unique dosage to smaller number of dosage, need for simple device, easy to use DPIs is well positioned for future application Vaccines Preferred inhalation device still to be assessed Biologics  Naïve users who need convenient mode of administration: alternative to injection, frequent usage, sophisticated by easy to use device Nasal routes Central nervous system Pain relief Migraines Macromolecules Anti-viral
  10. 10. Summary of Capsule- Based Delivery Systems
  11. 11. Summary of Capsule-based Devices  Spiriva® HandiHaler® (tiotropium bromide inhalation  powder) is an inhaled once-a-day maintenance  prescription treatment for bronchospasm (airway  narrowing) associated with chronic obstructive pulmonary  disease (COPD).  Inhalation device: Handihaler Atrovent is used to prevent bronchospasm, or  narrowing airways in the lungs, in people with  bronchitis, emphysema, or COPD (chronic  obstructive pulmonary disease). Inhalation  device: Aerohaler Multidose
  12. 12. Summary of Capsule-based Devices Foradil relaxes the muscles in the walls of the  airways, allowing them to expand. Taken on a twice- daily basis, it helps to control asthma in people who  need regular treatment with short-acting inhalers,  including people with nighttime asthma. Regular twice- daily use can also relieve tightening of the airways in  people with Chronic Obstructive Pulmonary Disease,  including chronic bronchitis and emphysema.   Inhalation device: Aerolizer Inhalation device:  Osmohaler:
  13. 13. Summary of Capsule-based Devices This drug relaxes the smooth muscle in the  lungs and dilates airways to improve  breathing. It is used in the treatment of  asthma, chronic bronchitis, and emphysema.  VENTOLIN ROTACAPS for Inhalation are  indicated for the prevention and relief of  bronchospasm in patients 4 years of age and  older with reversible obstructive airway  disease and for the prevention of exercise- induced bronchospasm in patients 4 years of  age and older. The VENTOLIN ROTACAPS  for Inhalation formulation is particularly useful  in patients who are unable to properly use the  pressurized aerosol form of albuterol or who  prefer an alternative formulation.   Inhalation device: Rotahaler and Spinhaler.
  14. 14. Summary of Capsule-based Devices The inhalation capsule Avessa is available as  Rheocaps Avessa 100 mcg, Avessa 250 mcg,  Avessa 500 mcg, depending on the severity of  Asthma.  Indian pharmaceutical major Ranbaxy  Laboratories Limited has launched Avessa  (Formoterol + Fluticasone) inhalation capsules in  India for the treatment of asthma. Ranbaxy  claims that this unique combination has been  launched for the first time in the world combining  the fastest acting Long Acting Beta 2 Agonist  Formoterol and the most potent inhaled  corticosteroid Fluticasone. The product is to be  used only with the Rheohaler - the world's first  capsule-based multi-dose dry powder inhaler,  Ranbaxy. Inhalation device: FlowCaps® - Rheohaler  (developed by Hovione) Inhalation device:  FlowCaps® - Rheohaler (developed  by Hovione)
  15. 15. Continuous improvement in DPI systems The key challenge for inhalation drug delivery systems is a  consistent and high lung deposition The first DPI systems had ~5 % lung deposition which has  been increased by 4 – 5 times meanwhile This has been achieved by optimization of the formulation the inhalation device the inhalation capsule Labiris & Dolovich 2003